These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 24973347)

  • 1. Psoriasis induced by thalidomide in a patient with multiple myeloma.
    Ferrazzi A; Zambello R; Russo I; Alaibac M
    BMJ Case Rep; 2014 Jun; 2014():. PubMed ID: 24973347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thalidomide-induced psoriasis in a patient with multiple myeloma.
    D'Arena G; Galdo G; Musto P
    Postgrad Med J; 2019 Mar; 95(1121):171. PubMed ID: 30808723
    [No Abstract]   [Full Text] [Related]  

  • 3. Thalidomide-induced organizing pneumonia.
    Feaver AA; McCune DE; Mysliwiec AG; Mysliwiec V
    South Med J; 2006 Nov; 99(11):1292-4. PubMed ID: 17195429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thalidomide in multiple myeloma.
    Rajkumar SV
    Oncology (Williston Park); 2000 Dec; 14(12 Suppl 13):11-6. PubMed ID: 11204667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma.
    Rajkumar SV; Witzig TE
    Cancer Treat Rev; 2000 Oct; 26(5):351-62. PubMed ID: 11006136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disseminated herpes simplex virus and varicella zoster virus coinfection in a patient taking thalidomide for relapsed multiple myeloma.
    Curley MJ; Hussein SA; Hassoun PM
    J Clin Microbiol; 2002 Jun; 40(6):2302-4. PubMed ID: 12037117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thalidomide gives food for thought in multiple myeloma.
    Burton A
    Lancet Oncol; 2006 Apr; 7(4):283-4. PubMed ID: 16598872
    [No Abstract]   [Full Text] [Related]  

  • 8. [Thalidomide for the treatment of refractory multiple myeloma].
    Kakimoto T; Hattori Y; Okamoto S
    Rinsho Ketsueki; 2002 May; 43(5):345-8. PubMed ID: 12096483
    [No Abstract]   [Full Text] [Related]  

  • 9. Leukocytoclastic vasculitis due to thalidomide in multiple myeloma.
    Yildirim ND; Ayer M; Küçükkaya RD; Alpay N; Mete O; Yenerel MN; Yavuz AS; Nalçaci M
    Jpn J Clin Oncol; 2007 Sep; 37(9):704-7. PubMed ID: 17709605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic dilemmas with thalidomide in multiple myeloma: case discussions.
    Desikan RK; Jagannath S
    Semin Oncol; 2001 Dec; 28(6):593-6. PubMed ID: 11740815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Thalidomide and others: new treatment for myeloma].
    Malphettes M; Fermand JP
    Rev Prat; 2003 Oct; 53(15):1633-5. PubMed ID: 14689905
    [No Abstract]   [Full Text] [Related]  

  • 12. Efficacy and safety of thalidomide in the treatment of multiple myeloma.
    Warzocha K; Kraj M; Pogłód R; Szpila T; Mendek-Czajkowska E; Chełstowska M; Tronina RH
    Acta Pol Pharm; 2008; 65(6):771-4. PubMed ID: 19172865
    [No Abstract]   [Full Text] [Related]  

  • 13. Thalidomide: present and future in multiple myeloma.
    Hussein MA
    Expert Rev Anticancer Ther; 2005 Feb; 5(1):25-31. PubMed ID: 15757435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Steven's Johnson syndrome with toxic epidermal necrolysis due to thalidomide in a case of multiple myeloma.
    Das A; Sil A; Mishra V; Das NK
    Indian J Pharmacol; 2014; 46(5):557-9. PubMed ID: 25298592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thalidomide and thrombosis.
    Mehta P
    Clin Adv Hematol Oncol; 2003 Aug; 1(8):464-5. PubMed ID: 16258433
    [No Abstract]   [Full Text] [Related]  

  • 16. Two cases of bacterial meningitis accompanied by thalidomide therapy in patients with multiple myeloma: is thalidomide associated with bacterial meningitis?
    Pasa S; Altintas A; Cil T; Ustun C; Bayan K; Danis R; Urakci Z; Tuzun Y; Ayyildiz O
    Int J Infect Dis; 2009 Jan; 13(1):e19-22. PubMed ID: 18621563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Completely reversible agranulocytosis in a multiple myeloma patient treated with thalidomide-dexamethasone.
    Magalini F; Stella A; Sansoni P
    Intern Emerg Med; 2008 Dec; 3(4):383-5. PubMed ID: 18320148
    [No Abstract]   [Full Text] [Related]  

  • 18. Intermediate dose thalidomide (200 mg daily) has comparable efficacy and less toxicity than higher doses in relapsed multiple myeloma.
    Wechalekar AD; Chen CI; Sutton D; Reece D; Voralia M; Stewart AK
    Leuk Lymphoma; 2003 Jul; 44(7):1147-9. PubMed ID: 12916866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pulmonary hypertension related to thalidomide therapy in refractory multiple myeloma.
    Antonioli E; Nozzoli C; Gianfaldoni G; Mannelli F; Rossi S; Betti S; Bernardeschi P; Fiorentini G; Bosi A
    Ann Oncol; 2005 Nov; 16(11):1849-50. PubMed ID: 16012178
    [No Abstract]   [Full Text] [Related]  

  • 20. Reversible dementia due to thalidomide therapy for multiple myeloma.
    Morgan AE; Smith WK; Levenson JL
    N Engl J Med; 2003 May; 348(18):1821-2. PubMed ID: 12724497
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.